188 related articles for article (PubMed ID: 18515467)
1. Clozapine: more than 900 mg/day may be needed.
Maccall C; Billcliff N; Igbrude W; Natynczuk S; Spencer EP; Flanagan RJ
J Psychopharmacol; 2009 Mar; 23(2):206-10. PubMed ID: 18515467
[TBL] [Abstract][Full Text] [Related]
2. Plasma clozapine concentration coefficients of variation in a long-term study.
Diaz FJ; de Leon J; Josiassen RC; Cooper TB; Simpson GM
Schizophr Res; 2005 Jan; 72(2-3):131-5. PubMed ID: 15560958
[TBL] [Abstract][Full Text] [Related]
3. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex).
Couchman L; Morgan PE; Spencer EP; Johnston A; Flanagan RJ
Ther Drug Monit; 2010 Oct; 32(5):624-7. PubMed ID: 20720516
[TBL] [Abstract][Full Text] [Related]
4. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
[TBL] [Abstract][Full Text] [Related]
6. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
Couchman L; Morgan PE; Spencer EP; Flanagan RJ
Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical correlates of "high-dose" clozapine therapy for treatment-refractory schizophrenia.
Buckley PF; Friedman L; Krowinski AC; Eaton Y; Tronetti M; Miller DD
Schizophr Res; 2001 Apr; 49(1-2):225-7. PubMed ID: 11428347
[No Abstract] [Full Text] [Related]
8. The significance of sampling time in therapeutic drug monitoring of clozapine.
Jakobsen MI; Larsen JR; Svensson CK; Johansen SS; Linnet K; Nielsen J; Fink-Jensen A
Acta Psychiatr Scand; 2017 Feb; 135(2):159-169. PubMed ID: 27922183
[TBL] [Abstract][Full Text] [Related]
9. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.
Rostami-Hodjegan A; Amin AM; Spencer EP; Lennard MS; Tucker GT; Flanagan RJ
J Clin Psychopharmacol; 2004 Feb; 24(1):70-8. PubMed ID: 14709950
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.
Wehring HJ; Elsobky T; McEvoy JP; Vyas G; Richardson CM; McMahon RP; DiPaula BA; Liu F; Sullivan K; Buchanan RW; Feldman S; McMahon EM; Kelly DL
Psychiatr Q; 2018 Mar; 89(1):73-80. PubMed ID: 28466366
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
[TBL] [Abstract][Full Text] [Related]
12. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.
Couchman L; Bowskill SV; Handley S; Patel MX; Flanagan RJ
Early Interv Psychiatry; 2013 May; 7(2):122-30. PubMed ID: 22747759
[TBL] [Abstract][Full Text] [Related]
13. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.
Tang YL; Mao P; Li FM; Li W; Chen Q; Jiang F; Cai ZJ; Mitchell PB
Br J Clin Pharmacol; 2007 Jul; 64(1):49-56. PubMed ID: 17298477
[TBL] [Abstract][Full Text] [Related]
14. Dosing strategies of clozapine-fluvoxamine cotreatment.
Lu ML; Lane HY; Jann MW; Chang WH
J Clin Psychopharmacol; 2002 Dec; 22(6):626-8. PubMed ID: 12454566
[No Abstract] [Full Text] [Related]
15. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.
Haslemo T; Eikeseth PH; Tanum L; Molden E; Refsum H
Eur J Clin Pharmacol; 2006 Dec; 62(12):1049-53. PubMed ID: 17089108
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
[TBL] [Abstract][Full Text] [Related]
17. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
[TBL] [Abstract][Full Text] [Related]
19. Unanticipated plasma concentrations in two clozapine-treated patients.
Alfaro CL; McClure RK; Vertrees JE; Benavides R
Ann Pharmacother; 2001 Sep; 35(9):1028-31. PubMed ID: 11573850
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.
Consoli G; Lastella M; Ciapparelli A; Catena Dell'Osso M; Ciofi L; Guidotti E; Danesi R; Dell'Osso L; Del Tacca M; Di Paolo A
Pharmacogenomics; 2009 Aug; 10(8):1267-76. PubMed ID: 19663671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
